story of the week
Nivolumab in Advanced Hepatocellular Carcinoma (CheckMate 040)
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Nivolumab in Patients With Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation and Expansion Trial
Lancet 2017 Apr 20;[EPub Ahead of Print], AB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, SP Choo, J Trojan, TH Welling, T Meyer, YK Kang, W Yeo, A Chopra, J Anderson, C Dela Cruz, L Lang, J Neely, H Tang, HB Dastani, I MeleroFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.